

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM675494

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A., as Administrative Agent		09/20/2021	National Banking Association: UNITED STATES

RECEIVING PARTY DATA

Name:	Azurity Pharmaceuticals, Inc.
Street Address:	841 Woburn Street
City:	Wilmington
State/Country:	MASSACHUSETTS
Postal Code:	01887
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 25

Property Type	Number	Word Mark
Serial Number:	88439326	AZURITY
Serial Number:	88452967	AZURITY PHARMACEUTICALS
Serial Number:	85688748	CP
Serial Number:	85688718	CUTISPHARMA
Serial Number:	87136398	FIRST
Serial Number:	76418087	FIRST
Serial Number:	75882933	FIRST RX
Serial Number:	87715534	FIRVANQ
Serial Number:	87451656	FIRVANQ
Serial Number:	88061929	HODUCA
Serial Number:	90231566	KONVOMEF
Serial Number:	85688764	ORAL SUSPENSION
Serial Number:	86299917	ORAL SOLUTION
Serial Number:	86749911	RXM THERAPEUTICS
Serial Number:	86749943	RXM THERAPEUTICS
Serial Number:	85688790	SUPPOSITORY
Serial Number:	88194921	THINK FIRST BEFORE YOU COMPOUND
Serial Number:	90400801	TONULAX
Serial Number:	90400789	TOPATEOS

TRADEMARK

Property Type	Number	Word Mark
Serial Number:	86540574	TRANSFORMING COMPOUNDING THROUGH INNOVAT
Serial Number:	87006120	TRANSFORMING MEDICINE THROUGH INNOVATION
Serial Number:	90400843	ZONISADE
Serial Number:	90400854	ZOPRON
Serial Number:	88453131	
Serial Number:	85688826	TOPICAL

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3129932652
Email: heather.poitras@lw.com
Correspondent Name: Heather Poitras
Address Line 1: 330 N Wabash Avenue
Address Line 4: Chicago, ILLINOIS 60611

ATTORNEY DOCKET NUMBER:	049067-0345 HP
NAME OF SUBMITTER:	Heather Poitras
SIGNATURE:	/hp/
DATE SIGNED:	09/20/2021

Total Attachments: 10

source=Azurity - JPM IP Release (126465508.1)#page1.tif
source=Azurity - JPM IP Release (126465508.1)#page2.tif
source=Azurity - JPM IP Release (126465508.1)#page3.tif
source=Azurity - JPM IP Release (126465508.1)#page4.tif
source=Azurity - JPM IP Release (126465508.1)#page5.tif
source=Azurity - JPM IP Release (126465508.1)#page6.tif
source=Azurity - JPM IP Release (126465508.1)#page7.tif
source=Azurity - JPM IP Release (126465508.1)#page8.tif
source=Azurity - JPM IP Release (126465508.1)#page9.tif
source=Azurity - JPM IP Release (126465508.1)#page10.tif

**RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY COLLATERAL**

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL** (this "Release"), dated as of September 20, 2021, is made by **JPMORGAN CHASE BANK, N.A.**, as Administrative Agent (the "Administrative Agent"), under the Credit Agreement referred to below (terms used in this Release and not herein defined shall have the meanings set forth in the Credit Agreement).

WHEREAS, in connection with that certain Credit Agreement (the "Credit Agreement"), dated as of April 15, 2021, among Cutispharma Intermediate Holdings, Inc. ("Holdings"), Azurity Pharmaceuticals, Inc., ("Borrower"), the Lenders party thereto and Administrative Agent, the Lenders agreed to make loans and extend other financial accommodations to or for the benefit of the Borrower;

WHEREAS, the Borrower, Holdings, certain other Subsidiaries of the Borrower (with Borrower and Holdings, the "Grantors") entered into those certain Pledge and Security Agreement, dated as of March 31, 2010 (the "Security Agreement"), dated as of April 15, 2021, in favor of the Administrative Agent;

WHEREAS, in connection with the Credit Agreement, Security Agreement and pursuant to those certain agreements described on Annex I attached hereto (collectively, the "IP Security Agreements"), the Grantors granted security interests in certain intellectual property owned by the Grantors, including those listed on Annex I attached hereto (the "IP Collateral"); and

WHEREAS, the IP Security Agreements were recorded in the United States Patent and Trademark Office, on the dates and on the reels/frames or volume/document no., as applicable, set forth on Annex I attached hereto.

NOW THEREFORE, in consideration of the material covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent hereby **RELEASES**, terminates and discharges, without representation, recourse or warranty whatsoever, all of its rights in, to and under, including its Lien on and security interest in, and right of setoff against, the IP Collateral, whether granted pursuant to the Security Agreement, the IP Security Agreements or any other agreement or document delivered in connection with the Credit Agreement, and the Administrative Agent hereby reassigns any and all such right, title and interest (if any) that the Administrative Agent may have in, to and under the IP Collateral to the relevant Grantor.


The Administrative Agent agrees, at the Grantors' sole expense, to cooperate with the Grantors and to provide the Grantors with the information and additional authorization reasonably required or desirable to effect the release of the Administrative Agent's security interest in the released collateral described herein.

This Release and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, the Administrative Agent has executed this Release as of the date first above written.

JPMORGAN CHASE BANK, N.A.,
as Administrative Agent

By: 
Name: Linda Secka
Title: Authorized Signatory

[Signature Page to Release of Security Interest in Intellectual Property Collateral]

TRADEMARK
REEL: 007425 FRAME: 0840

Supplemental Confirmatory Grant of Security Interest in United States Patents dated as of April 15, 2021, by Azurity Pharmaceuticals, Inc., a Delaware corporation, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on April 16, 2021 at Reel/Frame No. 055938/0859.

Short Title	Country	Application No.	Filing Date	Patent No.	Issue Date
COMPOSITIONS AND KITS FOR COMPOUNDING PHARMACEUTICALS	United States	09/707783	11/7/2000	6708822	3/23/04 Expired November 7, 2020
CONTAINER AND KIT FOR THE PREPARATION, STORAGE AND DISPENSING OF COMPOUNDED SUPPOSITORIES	United States	11/093178	3/29/05	7434690	10/14/08
CONTAINER AND KIT FOR THE PREPARATION, STORAGE AND DISPENSING OF COMPOUNDED SUPPOSITORIES	United States	12/207957	9/10/08	7815929	10/19/10
CONTAINER AND KIT FOR THE PREPARATION, STORAGE AND DISPENSING OF COMPOUNDED SUPPOSITORIES	United States	12/902260	10/12/10	8276757	10/02/12
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	15/791717	10/24/17	10,493,028	12/3/2019
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	WO2015/138983	3/13/15 National Phase		
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	15/126059	9/14/16	10,959,946	3/30/2021
CONTAINER AND METHOD FOR THE PREPARATION, STORAGE AND DISPENSING OF COMPOUNDED SUPPOSITORIES	United States	15/006745	1/26/16	9918903	3/20/18
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	16/676325	11/06/2019	10,688,046	6/23/2020
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	16/892,421	06/04/2020	10,959,947	3/30/2021
COMPOSITION AND MEHTOD FOR VANCOMYCIN ORAL LIQUID	United States	16/941,414	7/28/2020	10,959,949	3/3/2021
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	16/941,400	7/28/2020	10,959,948	3/3/2021
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	16/988,387	8/7/2020		
COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID	United States	17/165754 Unpublished	2/2/2021		

Short Title	Country	Application No.	Filing Date	Patent No.	Issue Date
APPARATUS AND METHOD FOR FILLING BULK MATERIALS INTO A CONTAINER	United States	WO2018017561	7/18/17 National Phase		
APPARATUS AND METHOD FOR FILLING BULK MATERIAL INTO A CONTAINER	United States	16/318819	1/18/2019		
AMLODIPINE FORMULATIONS	United States	16/927,664	7/13/2020	10,959,991	3/30/2021
AMLODIPINE FORMULATIONS	United States	16/927,678	7/13/2020	10,952,998	3/23/2021
AMLODIPINE FORMULATIONS	United States	16/853,380	4/20/2020	10,894,039	1/19/2021
AMLODIPINE FORMULATIONS	United States	15/726,901	10/06/17	10,695,329	6/30/2020
AMLODIPINE FORMULATIONS	United States	17/194,016 Unpublished	3/5/2021		
AMLODIPINE FORMULATIONS	United States	16/381,575	04/11/19	10799453	10/13/2020
AMLODIPINE FORMULATIONS	United States	17/067,396	10/9/2020		
COMPOSITION AND METHOD FOR PROTON PUMP INHIBITOR SUSPENSION	United States	16/310,675	12/17/2018		
COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION	United States	16/513,604	7/16/2019	10,751,333	8/25/2020
COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION	United States	17/017,295	9/10/2020		
COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION	United States	16/998,731	8/20/2020		
SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN	United States	17/133,415 Unpublished	12/23/2020		
POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGINE	United States	16/171,914	10/26/2018	10,653,626	5/19/2020
ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF	United States	16/354,764	3/15/2019		





Supplemental Confirmatory Grant of Security Interest in United States Patents dated as of April 15, 2021, Silvergate Pharmaceuticals, Inc., a Delaware corporation, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on April 16, 2021 at Reel/Frame No. 055938/0895.



Short Title	Country	Application No.	Filing Date	Patent No.	Issue Date
LISINOPRIL FORMULATIONS		16/822,412	3/18/20	10,940,177	3/9/21
LISINOPRIL FORMULATIONS		16/295,482	03/07/19	10,406,199	9/10/2019
LISINOPRIL FORMULATIONS		16/053,164	8/2/18	10,265,370	4/23/19
LISINOPRIL FORMULATIONS		15/805,934	11/7/17	10,039,800	8/07/18
LISINOPRIL FORMULATIONS		15/483,691	4/10/17	9,814,751	11/14/17
LISINOPRIL FORMULATIONS		15/268,095	9/16/16	9,616,096	4/11/17
LISINOPRIL FORMULATIONS		14/934,752	11/6/15	9,463,183	10/11/16
LISINOPRIL FORMULATIONS		17/194,021 Unpublished	3/5/2021		
ENALAPRIL FORMULATIONS		16/991,575	8/12/2020	10,918,621	2/16/2021
ENALAPRIL FORMULATIONS		16/883,553	5/26/2020	10,799,476	10/13/2020
ENALAPRIL FORMULATIONS		16/242,898	01/08/19	10,772,868	9/15/2020
ENALAPRIL FORMULATIONS		16/177,159	10/31/18	10,786,482	9/29/2020
ENALAPRIL FORMULATIONS		16/003,994	6/8/18	10,154,987	12/18/18
ENALAPRIL FORMULATIONS		15/802,341	11/2/17	10,039,745	8/07/18
ENALAPRIL FORMULATIONS		15/613,622	6/5/17	9,808,442	11/07/17
ENALAPRIL FORMULATIONS		15/081,603	3/25/16	9,669,008	6/06/17
ENALAPRIL FORMULATIONS		17/150,587 Unpublished	1/15/2021		
ENALAPRIL FORMULATIONS		17/228,024 Unpublished	4/12/2021		
ENALAPRIL COMPOSITIONS		15/850,732	12/21/17	9,968,553	5/15/18

Short Title	Country	Application No.	Filing Date	Patent No.	Issue Date
ENALAPRIL COMPOSITIONS		15/433,743	2/15/17	9,855,214	1/2/18
ENALAPRIL COMPOSITIONS		13/914,452	6/10/13	8,778,366	7/15/14
ENALAPRIL COMPOSITIONS		13/670,355	11/6/12	8,568,747	10/29/13
LISINOPRIL FORMULATIONS		16/564904	9/9/2019		

Supplemental Confirmatory Grant of Security Interest in United States Trademarks dated as of April 15, 2021, Azurity Pharmaceuticals, Inc., a Delaware corporation, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on April 16, 2021 at Reel/Frame No. 7257/0955.

Title	Country	Application No.	Application Date	Registration No.	Registration Date
AZURITY	United States	88/439326	5/21/19	6196161	11/10/20
 AZURITY PHARMACEUTICALS	United States	88/452967	5/30/19	6206671	11/24/20
 CP	United States	85688748	7/27/12	4420640	10/22/13
CUTISPHARMA	United States	85688718	7/27/12	4473417	1/28/14
 FIRST	United States	87136398	8/12/16	5244475	7/18/17
 FIRST	United States	76418087	6/7/02	3275609	8/7/07
 FIRST RX	United States	75882933	12/29/99	2636155	10/15/02
 FIRVANQ	United States	87715534	12/11/17	5651067	1/8/19
FIRVANQ	United States	87451656	5/16/17	5525903	7/24/18
HODUCA	United States	88/061929	8/1/18		
KONVOMEP	United States	90/231566	10/2/20		
 ORAL SUSPENSION	United States	85688764	7/27/12	4416915	10/15/13

Title	Country	Application No.	Application Date	Registration No.	Registration Date
 ORAL SOLUTION	United States	86299917	6/4/14	4678283	1/27/15
RXM THERAPEUTICS	United States	86749911	9/8/15	5498187	6/19/18
 RXM THERAPEUTICS	United States	86749943	9/8/15	5623056	12/4/18
 SUPPOSITORY	United States	85688790	7/27/12	4416916	10/15/13
THINK FIRST BEFORE YOU COMPOUND	United States	88/194921	11/15/18	5875744	10/1/19
TONULAX	United States	90/400801	12/22/20		
TOPATEOS	United States	90/400789	12/22/20		
TRANSFORMING COMPOUNDING THROUGH INNOVATION	United States	86540574	2/20/15	5055386	10/4/16
TRANSFORMING MEDICINE THROUGH INNOVATION	United States	87006120	4/19/16	5360667	12/19/17
ZONISADE	United States	90/400843	12/22/20		
ZOPRON	United States	90/400854	12/22/20		
 MISC DESIGN	United States	88/453131	5/30/19	6206673	11/24/20
TOPICAL	United States	85688826	7/27/2012	4615796	7/22/2014
AZURITY	Madrid (CA, CN, EU)	A0090745	17-Oct-2019	1502744	17-Oct-2019
AZURITY	GB	1502744	17-Oct-2019	81502744	17-Oct-2019
FIRVANQ	CA	1859135	25-Sep-2017	TMA1056990	1-Oct-2019

Title	Country	Application No.	Application Date	Registration No.	Registration Date
FIRVANQ	EM	017232752	21-Sep-2017	017232752	22-Mar-2018
FIRVANQ	GB	017232752	21-Sep-2017	9017232752	22-Mar-2018
KONVOMEPE	Madrid (CA, EU, UK)	A0106244	9-Mar-2021		
RXM THERAPEUTICS	CN	19256574	9-Mar-2016	19256574	13-Apr-2017
	CA	1771137	7-Mar-2016	TMA1026755	17-Jun-2019
	Madrid (CN, EU, IN, JP)	A0057109	7-Mar-2016	1296679	7-Mar-2016
TRANSFORMING MEDICINE THROUGH INNOVATION	CA	1800763	16-Sep-2016	TMA1027608	18-Jun-2019
TRANSFORMING MEDICINE THROUGH INNOVATION	EM	15819171	13-Sep-2016	15819171	22-Mar-2017
VANFYRST	EU	017232802	21-Sep-2017	017232802	22-Mar-2018
VANFYRST	GB	017232802	21-Sep-2017	9017232802	22-Mar-2018

Supplemental Confirmatory Grant of Security Interest in United States Trademarks dated as of April 15, 2021, Silvergate Pharmaceuticals, Inc., a Delaware corporation, in favor of Administrative Agent, was recorded with the U.S. Patent and Trademark Office on April 16, 2021 at Reel/Frame No. 7258/0065.

Title	Country	Application No.	Application Date	Registration No.	Registration Date
SILVERGATE	United States	85135713	9/22/10	4564423	7/8/14